India Pharmacists Ban Sales Of Combo Drugs With Safety Issues (India)
This article was originally published in PharmAsia News
Despite a court stay against a proposed government ban on combination drugs, most of India's retail pharmacists plan to refuse to sell them. The All India Organization of Chemists and Druggists, which represents two-thirds of pharmacists in India, said it was following a directive of the regulatory authority to withdraw licenses of combination drugs that failed to comply with quality standards. The drugs, which account for more than 10 percent of retail pharmacy drug sales in the country, had been approved without having undergone proper quality-safety tests. Regulators count 186 new applications for the combinations that involve combining two or more already-approved drugs into a single formulation, and 50 of them have been rejected so far because of inadequate proof of quality and efficacy. (Click here for more
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.